Repligen gets first milestone payment from Pfizer for SMA program

Repligen (RGEN) receives its first $1M milestone payment from Pfizer (PFE) related to the companies' licensing agreement for spinal muscular atrophy compounds.

RGEN received $5M upfront and is eligible to receive as much as $64M more under the terms of the deal, not including royalties from any marketed compounds.

The spinal muscular atrophy program was out-licensed to PFE in order to allow RGEN to focus on its bioprocessing business while still preserving the economic value of the therapeutics business for shareholders. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs